Holen Sie sich die Stockscreener-App
205.01
2.10%
4.22
Vorhandelsmarkt:
203.92
-1.09
-0.53%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DHR?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$200.79
Offen:
$201.41
24-Stunden-Volumen:
4.24M
Relative Volume:
0.93
Marktkapitalisierung:
$145.10B
Einnahmen:
$24.78B
Nettoeinkommen (Verlust:
$3.68B
KGV:
39.62
EPS:
5.1743
Netto-Cashflow:
$5.29B
1W Leistung:
+4.61%
1M Leistung:
+13.05%
6M Leistung:
-13.13%
1J Leistung:
+6.06%
1-Tages-Spanne:
$200.36
$205.28
1-Wochen-Bereich:
$195.05
$205.28
52-Wochen-Spanne:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Firmenname
Danaher Corp
Sektor
Branche
Telefon
(202) 828-0850
Adresse
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
205.01 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
543.19 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
576.07 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
269.83 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
136.10 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2025-03-14 | Hochstufung | Stifel | Hold → Buy |
| 2025-02-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-31 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Eingeleitet | HSBC Securities | Hold |
| 2023-12-13 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2023-12-07 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-01 | Eingeleitet | SVB Securities | Outperform |
| 2023-04-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-10-24 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-17 | Fortgesetzt | Bernstein | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-06-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Eingeleitet | Bernstein | Outperform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-10 | Bestätigt | BofA Securities | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Buy |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-04-07 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-03 | Fortgesetzt | Barclays | Overweight |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Fortgesetzt | Stifel | Hold |
| 2019-10-28 | Bestätigt | Needham | Buy |
| 2019-10-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-19 | Bestätigt | Needham | Buy |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2019-02-25 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-04-20 | Bestätigt | Stifel | Buy |
Alle ansehen
Danaher Corp Aktie (DHR) Neueste Nachrichten
Danaher (DHR) Stock May Trade At A Discount Despite Its 18% Five Year Decline - Yahoo Finance
Danaher stock holds near its 52-week range - ad-hoc-news.de
Lobbying Update: $36,000 of DANAHER CORPORATION lobbying was just disclosed - Quiver Quantitative
Can Masimo’s Integration and Bioprocessing Strength Reshape Danaher’s Long-Term Story (DHR)? - Yahoo Finance
Top Research Reports for Interactive Brokers, Danaher & S&P Global - Yahoo Finance
Form 4 Danaher Corporation For: 16 July By Investing.com - Investing.com Canada
Danaher Corp (NYSE: DHR) VP details 60-share stock tax withholding - Stock Titan
Danaher (NYSE: DHR) director exercises options, 3,298 shares acquired - Stock Titan
Danaher (NYSE: DHR) director Linda Filler exercises 3,298 stock options - Stock Titan
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Danaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing? - TradingView
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Danaher stock holds steady as diversified life sciences portfolio underpins long-term growth - ad-hoc-news.de
Global Biochemistry Analyzer Market to Reach $8.18 Billion by 2035 as Diagnostic Testing Demand Accelerates - GlobeNewswire Inc.
Lab-products maker StatLab set to join Danaher’s Leica - Stock Titan
Implied Volatility Surging for Danaher Stock Options - Yahoo Finance
Form 144 DANAHER CORP /DE/ For: 14 July - Investing.com UK
Form 144 DANAHER CORP /DE/ For: 14 July By Investing.com - Investing.com India
[144] DANAHER CORP /DE/ SEC Filing - Stock Titan
Danaher stock may move 4.9% on July 21 earnings report By Investing.com - Investing.com South Africa
Danaher stock may move 4.9% on July 21 earnings report - Investing.com
XS335208293 Bond Profile — Key Metrics - TradingView
Danaher stock holds steady as diversified diagnostics and life sciences portfolio supports long term - Ad Hoc News
US235851AW2 Bond Profile — Key Metrics - TradingView
Danaher stock holds steady as investors await the next catalyst - Ad Hoc News
Danaher stock holds steady as its life sciences platform stays central - Ad-hoc-news.de
Danaher stock holds steady as analysts frame the outlook - ad-hoc-news.de
Danaher Is Getting Better, But The Stock Still Isn't Cheap (NYSE:DHR) - Seeking Alpha
Danaher-Masimo close caps med tech’s strongest first-half since 2022 - BioWorld News
Danaher stock reflects diversified health care tools business context - ad-hoc-news.de
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Danaher Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Will Strength in Biotechnology Unit Continue to Drive DHR's Growth? - The Globe and Mail
The AEROFLOW PFT System. Danaher leans into precise pulmonary testing - AD HOC NEWS
COMPASS CAPITAL MANAGEMENT, INC's Danaher Corp(DHR) Holding History - GuruFocus
Danaher Corp. highlights diversified life-sciences portfolio as investors weigh long-term growth - ad-hoc-news.de
Danaher Corp. stock underperforms Monday when compared to competitors - MarketWatch
DHR Maintained by Evercore ISI Group -- Price Target Lowered to $230 - GuruFocus
Danaher slips as investors weigh soft diagnostics trends and Masimo integration risk - Quiver Quantitative
DHRDanaher Corp Latest SEC Filings - Finviz
Danaher Corp. focuses on life sciences growth as investors watch long-term strategy - AD HOC NEWS
Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders? - Morningstar
What to Expect From Danaher's Next Quarterly Earnings Report - Barchart.com
Railway Pension Investments Ltd's Danaher Corp(DHR) Holding History - GuruFocus
Danaher Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Danaher Corp. focuses on diversified science tools as investors weigh long term growth - AD HOC NEWS
Danaher Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Danaher Corp adjusts guidance after Masimo deal. Analysts highlight cautious upside for the stock - AD HOC NEWS
Deals tracker: Select Medical Holdings acquisition moves forward - Modern Healthcare
$1M Danaher grant targets Ebola outbreak in Congo, Uganda - Stock Titan
Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation - Insider Monkey
Finanzdaten der Danaher Corp-Aktie (DHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.48%
2.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):